Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

@inproceedings{Furqan2012DysregulationOJ,
  title={Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application},
  author={Muhammad Mohsin Furqan and Nikhil Mukhi and Byung Ick Lee and Delong Liu},
  booktitle={Biomarker Research},
  year={2012}
}
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction of extracellular signals from cytokines and growth factors involved in hematopoiesis, immune regulation, fertility, lactation, growth and embryogenesis. JAK family contains four cytoplasmic tyrosine kinases, JAK1-3 and Tyk2. Seven STAT proteins have been identified in human cells, STAT1-6, including STAT5a and STAT5b. Negative regulators of JAK–STAT pathways include… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 108 references

An Expanded Multicenter Phase I/ II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis

  • A Pardanani, J Gotlib, +7 authors G Smith
  • ASH Annual Meeting Abstracts
  • 2011
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…